Brokers Set Expectations for 908 Devices Inc.’s Q1 2025 Earnings (NASDAQ:MASS)

908 Devices Inc. (NASDAQ:MASS) – Stock analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for 908 Devices in a research note issued to investors on Tuesday, April 30th. William Blair analyst M. Larew anticipates that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. William Blair also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.19) EPS.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.03. The business had revenue of $9.99 million for the quarter, compared to the consensus estimate of $9.29 million. 908 Devices had a negative return on equity of 20.47% and a negative net margin of 68.57%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.39) EPS.

908 Devices Stock Performance

Shares of MASS opened at $5.65 on Thursday. The stock has a market capitalization of $186.34 million, a PE ratio of -5.28 and a beta of 1.02. The company’s fifty day moving average is $6.54 and its 200 day moving average is $7.06. 908 Devices has a fifty-two week low of $4.85 and a fifty-two week high of $12.51.

Institutional Trading of 908 Devices

A number of large investors have recently made changes to their positions in MASS. AWM Investment Company Inc. bought a new position in shares of 908 Devices in the 3rd quarter valued at about $3,740,000. ARK Investment Management LLC raised its position in 908 Devices by 8.3% during the fourth quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company’s stock valued at $48,769,000 after purchasing an additional 333,119 shares during the period. Iron Triangle Partners LP lifted its stake in shares of 908 Devices by 31.1% in the 4th quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company’s stock valued at $14,417,000 after purchasing an additional 304,484 shares during the last quarter. Granahan Investment Management LLC boosted its holdings in shares of 908 Devices by 10.6% in the 4th quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company’s stock worth $22,874,000 after purchasing an additional 195,368 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of 908 Devices by 3.0% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company’s stock valued at $4,196,000 after purchasing an additional 18,492 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.